Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

lungcancer

Add ILCN as a preferred source
  • Afatinib Outperforms Gefitinib in Advanced Non-Small Cell Lung Cancer

    Afatinib Outperforms Gefitinib in Advanced Non-Small Cell Lung Cancer

    By

    Systemic, Targeted, & Immune Therapies

    By Erik J. MacLaren, PhD The pan-ErbB inhibitor afatinib (Gilotrif) improves progression-free survival (PFS), time-to-treatment-failure (TTF) rate, and objective response rate (ORR) compared to the first-generation EGFR inhibitor gefitinib (Iressa) as a first-line treatment in patients with EGFR mutation-positive NSCLC, according to results presented at the ESMO Asia 2015 Congress in Singapore.1 Afatinib and gefitinib…

View ILCN Archives

Provider Resources

Popular Articles

  • Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection

  • Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy

  • Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC

  • No “Known” Risk Factors: The Health Consequences of Radiation Therapy

  • Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging

  • No PFS, OS Benefit Seen in Final Results from PACIFIC-2

  • WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers

  • Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture

  • A Holistic Approach to Patient Care